Prevention, diagnosis, and treatment of cervical cancer (Q37021701)

17 August 2017

1 reference

title

Prevention, diagnosis, and treatment of cervical cancer (English)

1 reference

17 August 2017

cervix uterine cancer

1 reference

Harry J Long

1

1 reference

17 August 2017

Nadia N I Laack

series ordinal

2

1 reference

17 August 2017

Bobbie S Gostout

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

82

1 reference

17 August 2017

12

1 reference

17 August 2017

1566-1574

1 reference

17 August 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Global cancer statistics, 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Condom use and the risk of genital human papillomavirus infection in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Human papillomavirus and cervical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

The functions of human papillomavirus type 11 E1, E2, and E2C proteins in cell-free DNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Prophylactic human papillomavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

International incidence rates of invasive cervical cancer after introduction of cytological screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Screening for cervical cancer and initial treatment of patients with abnormal results from papanicolaou testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

The 2001 Bethesda System: terminology for reporting results of cervical cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Natural history of cervicovaginal papillomavirus infection in young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Natural history of dysplasia of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Human papillomavirus update with a particular focus on cervical disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Progression and regression of cervical lesions. Review of smears from women followed without initial biopsy or treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Tumor and treatment factors improving outcome in stage III-B cervix cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

The hazard of accelerated tumor clonogen repopulation during radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

The effect of treatment duration in the local control of cervix cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2961104-X

10.1016/S0025-6196(11)61104-X

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference